Video

Dr. Tsai on Ongoing Research Efforts in Pancreatic Cancer

Susan Tsai, MD, MHS, discusses ongoing research efforts being made in the realm of pancreatic cancer. 

Susan Tsai, MD, MHS, associate professor, division of surgical oncology, department of surgery, director, LaBahn Pancreatic Cancer Program, director, Medical College of Wisconsin surgical oncology biorepository and pancreatic cancer clinical database, discusses ongoing research efforts being made in the realm of pancreatic cancer. 

An ongoing randomized trial that is being conducted at the Medical College of Wisconsin is comparing conventional fractionation with a hypofractionated stereotactic body radiation therapy approach in this patient population, according to Tsai. Another investigator-initiated trial is examining the use of standard FOLFIRINOX in patients with pancreatic cancer and then switching them to an alternative therapy if they do not demonstrate a 50% decline in their CA 19-9 radioimmunoassay levels or achieve a robust clinical response, Tsai explains.

Finally, a precision medicine trial is also being conducted. For this effort, patients will undergo a biopsy and receive a chemotherapy regimen that best corresponds with their cancer subtype, Tsai says. This is the first clinical trial to utilize subtyping to inform the use of neoadjuvant therapy, Tsai concludes.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Latest CME

View All
Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC
Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Jun 6th 2025 - Jul 12th 2025

online-activity
Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation
Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Jun 6th 2025 - Jul 12th 2025

online-activity
Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing
Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Jun 5th 2025 - Jul 12th 2025

online-activity